Diagnostic value of peripheral blood miR‐296 combined with vascular endothelial growth factor B on the degree of coronary artery stenosis in patients with coronary heart disease

Article

作者: Ji, Ningning ; Wang, Yu ; Fu, Ting ; Xu, Lei

AbstractObjectiveCoronary heart disease (CHD) is a disorder resulting from organic and functional coronary artery stenosis (CAS), thus causing reduced oxygenated blood in the heart. miRNAs are useful biomarkers in the diagnosis of atherosclerosis, CHD, and acute coronary syndrome. Vascular endothelial growth factor (VEGF) is closely related to CHD. This study explored the correlation of miR‐296 and VEGF‐B expression levels in peripheral blood with CAS degree in CHD patients.MethodsTotally 220 CHD patients were enrolled and classified into mild‐(71 cases)/moderate‐(81 cases)/severe‐CAS (68 cases) groups, with another 80 healthy cases as controls. The serum miR‐296 and VEGF‐B expression levels were detected using reverse transcription quantitative polymerase chain reaction. The correlation between miR‐296 and CAS‐related indexes was assessed via Pearson analysis. The binding relationship of miR‐296 and VEGF‐B was first predicted and their correlation was further analyzed via the Pearson method. The clinical diagnostic efficacy of miR‐296 or VEGF‐B on CAS degree was evaluated by the receiver operating characteristic curve.ResultsSerum miR‐296 was downregulated in CHD patients and was the lowest in patients with severe‐CAS. miR‐296 was negatively‐correlated with high‐sensitivity C‐reactive protein, brain natriuretic peptide, and cardiac troponin I. miR‐296 targeted VEGF‐B. VEGF‐B was upregulated in CHD patients and inversely‐related to miR‐296. Low expression of miR‐296 and high expression of VEGF‐B both had high clinical diagnostic values on CAS degree in CHD patients. miR‐296 combined with VEGF‐B increased the diagnostic value on CAS.ConclusionLow expression of miR‐296 combined with high expression of its target VEGF‐B predicts CAS degree in CHD patients.

2022-09-01·European Journal of Pharmacology

The key roles of non-coding RNAs in the pathophysiology of hypertension

Review

作者: Samsami, Majid ; Ghafouri-Fard, Soudeh ; Hussen, Bashdar Mahmud ; Taheri, Mohammad ; Shirvani-Farsani, Zeinab

Hypertension is a multifactorial condition in which several genetic and environmental elements contribute. Recent investigations have revealed contribution of non-coding region of the transcriptome in this trait. CDKN2B-AS1, AK098656, MEG3, H19, PAXIP1-AS1, TUG1, GAS5, CASC2 and CPS1-IT are among long non-coding RNAs participating in the pathophysiology of hypertension. Several miRNAs have also been found to be implicated in this disorder. miR-296, miR-637, miR-296, miR-637, hsa-miR-361-5p, miR-122-5p, miR-199a-3p, miR-208a-3p, miR-423-5p, miR-223-5p and miR-140-5p are among dysregulated miRNAs in this condition whose application as diagnostic biomarkers for hypertension has been evaluated. Finally, hsa-circ-0005870, hsa_circ_0037911 and hsa_circ_0014243 are examples of dysregulated circular RNAs in hypertensive patients. In the current review, we describe the role of these non-coding RNAs in the pathophysiology of hypertension.

2022-08-01·Advanced Therapeutics

Inhaled Gold Nano‐Star Carriers for Targeted Delivery of Triple Suicide Gene Therapy and Therapeutic MicroRNAs to Lung Metastases: Development and Validation in a Small Animal Model

Article

作者: Massoud, Tarik F. ; Krishnan, Anandi ; Seetharam, Sumanth Mosale ; Sukumar, Uday Kumar ; Liu, Yi ; Jugniot, Natacha ; Paulmurugan, Ramasamy ; Rengaramachandran, Adith ; Mukherjee, Pinaki ; Sadeghipour, Negar

AbstractPulmonary metastases pose treatment challenges for many cancers, including triple‐negative breast cancer (TNBC). A novel suicide gene and therapeutic microRNAs (miRs) combination therapy against lung metastases in vivo is tested in mouse models after intranasal delivery using nontoxic gold nanoparticles (AuNPs) formulated to carry these molecular therapeutics. AuNPs coated with chitosan‐β‐cyclodextrin (CS‐CD) are used and functionalized with a urokinase plasminogen activator (uPA) peptide to carry triple cancer suicide genes (thymidine kinase‐p53‐nitroreductase: TK‐p53‐NTR) plus therapeutic miRNAs (antimiR‐21, antimiR‐10b and miR‐100). Three AuNPs are synthesized: 20 nm gold nanodots (AuND), and 20 nm or 50 nm nanostars (AuNS), all surface coated with CS‐CD using a microfluidic‐optimized method. These positively charged AuNP‐CS‐CD cores are sequentially coated with synthetic miRNAs followed by TK‐p53‐NTR via electrostatic interactions, and uPA peptide is added through CD‐adamantane hostguest chemistry. Transfection efficiency comparisons for different AuNPs shows 50 nm AuNS allows ≈4.16‐fold higher gene transfection than other AuNPs. Intranasal delivery of uPA‐AuNS‐TK‐p53‐NTR‐microRNAs NPs (pAuNS@TK‐p53‐NTR‐miRs) in mice predominantly accumulates in lungs and facilitates ganciclovir and CB1954 prodrug‐mediated gene therapy against TNBC lung metastases. This new nanosystem can serve as an adaptable‐across‐cancer‐type, facile, and clinically scalable platform to allow future inhalational suicide gene‐miR combination therapy for patients harboring pulmonary metastases.

100 项与 Anti-miR-10b 相关的药物交易

登录后查看更多信息